ProCE Banner Activity

Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC

Slideset Download
Conference Coverage
Lorlatinib is well tolerated in ALK+ and ROS1+ NSCLC and shows antitumor activity, including intracranial activity, in patients pretreated with available inhibitors of ALK and ROS1.

Released: June 07, 2016

Expiration: June 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals